Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction.
D000281:Administration, Intranasal; D000293:Adolescent; D000328:Adult; D004311:Double-Blind Method; D007172:Erectile Dysfunction / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010410:Penile Erection / Q000187:drug effects; D010456:Peptides, Cyclic / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics*; D010919:Placebos; D044101:Receptors, Melanocortin / Q000819:agonists*; D012720:Severity of Illness Index; D016896:Treatment Outcome; D000521:alpha-MSH
D010456:Peptides, Cyclic; D010919:Placebos; D044101:Receptors, Melanocortin; D000521:alpha-MSH; C476721:bremelanotide